Milae Bioresources Co. Ltd (218150) fair value: what the stock is really worth
As of Sep 23, 2026: fair value of Milae Bioresources Co. Ltd KRW 3,474, price KRW 1,920, upside +80.9%, quality 60 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Watch Milae Bioresources Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for freePro now: $1 first month
Milae Bioresources Co., Ltd. provides feed additives in Korea. It also offers processed feed, feed preservatives, and feed ingredients. In addition, the company offers minerals and other specialty feed additives. The company was founded in 1998 and is based in Seoul, South Korea.
Stock analysis
Milae Bioresources Co. Ltd (218150) currently trades at 1,920 KRW, while our model-based Fair Value estimate is 3,474 KRW, implying the stock looks roughly 44.7% undervalued today.
Show more
Valuation
Bull case: the Growth DCF group reads highest at a median of 3,408 KRW per share, and 7 of the 10 models we run sit above the 1,920 KRW price.
Bear case: the Multiples group reads lowest at 838.87 KRW, and 3 of the 10 models stay below the price. Evidence for this calculation is low.
Scenario range: 2,346 KRW (bear) to 4,903 KRW (bull), the price of 1,920 KRW sits below it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 60/100 (solid quality), in the Consumer Defensive sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Milae Bioresources Co. Ltd reported revenue of 67.6B KRW in FY2025 versus 66.7B KRW in FY2021, a compound +0.3%/yr. Reported net income was −3.3B KRW in FY2025.
Key figures
Market cap 37.4B KRW (≈ $27.5M) · P/S ratio 0.57 · Net margin −4.8% · Return on equity −6.8% · Return on assets (EBIT) 0.4% · Operating margin 2.6% · Revenue (TTM) 69.9B KRW · Revenue growth (YoY) +15.9%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 45% below its 52-week high and 18% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Consumer Defensive peers we cover trades at 10% fair-value upside, at 81%, 218150 screens cheaper than that median.
Fair Value models
Bear 2,346 KRWFair Value 3,474 KRWBull 4,903 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.37/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
+8.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−3.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.3%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.5%
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.0% (2020) → −2.1% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed
Growth Forecast
Little optimism in the price
The price assumes less growth than the company has delivered so far.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
−7.8%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect
n/a
No analyst forecast available.
After inflation (South Korea: IMF forecast 2.1% a year to 2030, 2.1% from 2016 to 2025) that is about −9.6% a year for the price.
Compare Milae Bioresources Co. Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Farm Products · 296 stocks
Beats the industry median on 5/8 measures
Overall it ranks above its industry peers.
Valuation
Quality Score60 · Above median
Fair Value upside+81% · Top 25%
Profitability
Return on assets−1% · Bottom 25%
Net margin (TTM)−5% · Bottom 25%
Operating margin (TTM)3% · Below median
Growth and dividend
Revenue growth16% · Above median
Balance sheet
Debt / equity0.00× · Lowest 25%
Valuation Multiplesvs Farm Products median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Milae Bioresources Co. Ltd (218150) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 3,474 KRW versus a price of 1,920 KRW, about +81% upside (undervalued).
What is the fair value of 218150?
Our model-based fair value for Milae Bioresources Co. Ltd is 3,474 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 1,920 KRW.
What is the quality score of 218150?
Milae Bioresources Co. Ltd has a Quality Score of 60/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Milae Bioresources Co. Ltd (218150)?
Our model-based price target is the fair value of 3,474 KRW (as of Sep 24, 2026) from 10 valuation models. Cautious scenario 2,346 KRW, optimistic scenario 4,903 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the Milae Bioresources Co. Ltd stock forecast for 2026?
Our models put fair value at 3,474 KRW, about +81% upside versus a price of 1,920 KRW (undervalued). Cautious scenario 2,346 KRW, optimistic scenario 4,903 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of Milae Bioresources Co. Ltd (218150)?
Milae Bioresources Co. Ltd reported trailing-twelve-month revenue of about 69.9B KRW (latest available figure, as of Sep 24, 2026).
What growth is priced into Milae Bioresources Co. Ltd (218150)?
For today's price to be fair in a discounted-cash-flow model, Milae Bioresources Co. Ltd would have to grow free cash flow by -7.8 % per year for five years (discount rate 8.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +7.3 % per year. As of Sep 24, 2026.
What discount rate (WACC) does the fair value of 218150 use?
Our models discount Milae Bioresources Co. Ltd at 8.9 %: a base by market capitalisation (nano), damped by beta 0.12, country premium for South Korea. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Milae Bioresources Co. Ltd that is -7.8 % per year a year over ten years, using the same discount rate (8.9 %) and the same formula as our fair value.
How much growth has Milae Bioresources Co. Ltd (218150) delivered so far?
Over the past 5 years revenue at Milae Bioresources Co. Ltd grew +7.3 % a year. The price currently implies -7.8 % per year free-cash-flow growth a year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Milae Bioresources Co. Ltd (218150) growing?
The median revenue growth in the sector is +2.9 % a year. That is the yardstick for the growth priced into Milae Bioresources Co. Ltd (-7.8 % per year a year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Milae Bioresources Co. Ltd (218150)?
The free-cash-flow yield on the price is 10.54 %: that much free cash flow Milae Bioresources Co. Ltd produces per unit of market value. When it exceeds the discount rate of our models (8.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Milae Bioresources Co. Ltd (218150)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Milae Bioresources Co. Ltd it is 3,474 KRW per share (as of Sep 24, 2026), against a price of 1,920 KRW. It is the blended result of 10 valuation models (cash flow, earnings, asset, dividend).
Is Milae Bioresources Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 218150 trades below its calculated fair value: price 1,920 KRW, fair value 3,474 KRW, a gap of about +81% (undervalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 218150?
No. The price is what the market pays today (1,920 KRW); the fair value is what the company's own numbers justify (3,474 KRW). For Milae Bioresources Co. Ltd the two are 1,554 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is Milae Bioresources Co. Ltd worth?
The market values Milae Bioresources Co. Ltd at about 37.4B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 1,920 KRW; our models calculate a fair value of 3,474 KRW per share.
What do the bullish and bearish scenarios say about 218150?
Our models span a range for Milae Bioresources Co. Ltd: cautious scenario 2,346 KRW, base 3,474 KRW, optimistic 4,903 KRW per share (as of Sep 24, 2026, price 1,920 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Milae Bioresources Co. Ltd (218150)?
Balance-sheet figures for Milae Bioresources Co. Ltd (as of Sep 24, 2026): return on equity −6.8%, debt of 0.00 per unit of equity. They feed the Quality Score of 60/100, which measures business quality independently of the share price.
How far is 218150 from its 52-week high?
Milae Bioresources Co. Ltd trades at 1,920 KRW, about 45% below its 52-week high of 3,470 KRW and 18% above the low of 1,622 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 3,474 KRW is for.
Which stocks are comparable to Milae Bioresources Co. Ltd?
From the same area (Consumer Defensive) we also value Archer-Daniels-Midland Company, Muyuan Foods Group, Bunge Global SA, Tyson Foods, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Milae Bioresources Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 1,920 KRW, calculated fair value 3,474 KRW (+81%), Quality Score 60/100, from 10 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 218150 calculated?
We run Milae Bioresources Co. Ltd through 10 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 3,474 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. Milae Bioresources Co. Ltd currently trades 81 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Milae Bioresources Co. Ltd (218150)?
The closing price on Sep 23, 2026 was 1,920 KRW. Our model-based fair value is 3,474 KRW, about +81% upside (undervalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Milae Bioresources Co. Ltd right now?
The price is below even our cautious bear case (2,346 KRW). The market is more pessimistic than our downside scenario. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid quality (60/100) at a price below fair value, the discount is the argument here, not the business quality. A fairly wide model range (2,346 KRW to 4,903 KRW) leaves room in how you read the outcome.
Key figures of Milae Bioresources Co. Ltd
How large is the market capitalisation of Milae Bioresources Co. Ltd (218150)?
The market capitalisation of Milae Bioresources Co. Ltd is 37.4B KRW (≈ $27.5M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Milae Bioresources Co. Ltd (218150)?
The price-to-sales ratio of Milae Bioresources Co. Ltd is 0.57 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Milae Bioresources Co. Ltd (218150)?
The net margin of Milae Bioresources Co. Ltd is −4.8% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Milae Bioresources Co. Ltd (218150)?
The return on equity (ROE) of Milae Bioresources Co. Ltd is −6.8% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Milae Bioresources Co. Ltd (218150)?
On an EBIT basis the return on assets of Milae Bioresources Co. Ltd is 0.4% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Milae Bioresources Co. Ltd (218150)?
The operating margin of Milae Bioresources Co. Ltd is 2.6% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Milae Bioresources Co. Ltd (218150)?
Revenue at Milae Bioresources Co. Ltd is growing +15.9% versus a year earlier (3y avg −3.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Milae Bioresources Co. Ltd (218150)?
Earnings per share at Milae Bioresources Co. Ltd are growing −5.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Milae Bioresources Co. Ltd (218150) carry?
The net debt of Milae Bioresources Co. Ltd is 3.0B KRW (fiscal year 2025, ≈ 0.8 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Milae Bioresources Co. Ltd in the live analysis
One click puts Milae Bioresources Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
